// App-Quantinova.ai

PO1010 : Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analysis from DECLARE-TIMI 58 Trial

Researchers

Presenter

  • Mosenzon Ofri

Principal Investigators

  • L Heerspink HiddoJan

  • Dwyer JamieP

  • Cahn Avivit

  • Goodrich EricaL

  • Rozenberg Aliza

  • Yanuv Ilan

  • Wilding JohnPh

  • Leiter LawrenceA

  • Bhatt DeepakL

  • Mcguire DarrenK

  • Ma RonaldC

  • Tankova Tsvetalina

  • Fredriksson Martin

  • Gause-Nilsson Ingrid A M I

  • Langkilde Anna Maria

  • Sabatine MarcS

  • Raz Itamar

Medical Centers

  • Hadassah Medical Center, Jerusalem, Israel

  • Brigham and Womens Hospital, Brookline, Massachusetts, United States

  • University Medical Center Groningen, Nijmegen, Netherlands

  • Vanderbilt University Medical Center Nashville TN USA Nashville Tennessee United States

  • Brigham and Womens Hospital, Brookline, Massachusetts, United States

  • Department of Cardiovascular and Metabolic Medicine University of Liverpool UK Liverpool United Kingdom

  • St Michael's Hospital, University of Toronto, Toronto, ON, Canada

  • UT Southwestern Medical Center, Dallas, Texas, United States

  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • Department of Endocrinology Medical University Sofia Bulgaria Sofia Bulgaria

  • Early RIA, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Locations

  • Israel

  • United States

  • Netherlands

  • United Kingdom

  • Canada

  • Bulgaria

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved